Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $10.5620, but opened at $11.06. Bayer Aktiengesellschaft shares last traded at $11.02, with a volume of 102,449 shares changing hands.
Analyst Ratings Changes
BAYRY has been the subject of a number of research reports. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Zacks Research raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.
Read Our Latest Analysis on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Stock Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The company had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.
In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.
Read More
- Five stocks we like better than Bayer Aktiengesellschaft
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
